ASCO 2015: Pembrolizumab Shows Promising Activity Against Head and Neck Cancer
0 Views
administrator
07/06/23
A 132-patient study indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC). The findings may fill a large unmet need for better treatments in this disease.
Overall, 57% of patients experienced some tumor shrinkage, and 24.8% had a marked decrease in tumor size known as partial or complete response. Pembrolizumab was active across a wide range of patient subgroups including those with HPV-positive and HPV-negative HNC.
Presented by Tanguy Seiwert, MD, University of Chicago, Chicago, IL at ASCO 2015, Chicago, IL
-
Category
Show more
Facebook Comments
![Actinic Keratosis Treatment and Cancer Potential - Eyelid, Face, and Neck [Dermatology Course 32/60]](https://i.ytimg.com/vi/ffcHWDpKZqQ/maxresdefault.jpg)
No comments found